ABLYNX RECEIVES A SECOND MILESTONE PAYMENT FROM NANOBODY® DISCOVERY
AND DEVELOPMENT ALLIANCE

(Thomson Reuters ONE) - GHENT, Belgium, 5 October 2009 - Ablynx [Euronext Brussels: ABLX],announced today that it has received an undisclosed milestone paymentfrom Novartis for an exclusive research license in one of theprogrammes that is a component of their ongoing Research andDevelopment alliance.Novartis and Ablynx are collaborating to discover and developtherapeutic Nanobodies® against targets that are difficult to addresswith conventional antibodies and their fragments.The alliance was entered into in December 2005, and extended in 2007and again in December 2008 for a further year. Under the terms ofthis ongoing agreement, Ablynx receives upfront fees, license feesand funding for research and development. In addition, Ablynx will beeligible for milestone payments and royalties upon commercialisation.Novartis has exclusive rights to develop and commercialise theNanobody® products resulting from the collaboration. Financial termsare not disclosed.Edwin Moses, CEO and Chairman of Ablynx, commented: "We are delightedthat a second Nanobody® programme from our collaboration withNovartis is advancing to the next stage and we look forward to seeingthese two programmes progressing towards development." -ends-For more information, please contact:For international media enquiries: College Hill Life SciencesSue Charles,Justine Lamond,Dr. John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr. Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1345773/323113.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 05.10.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 6581
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 257 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX RECEIVES A SECOND MILESTONE PAYMENT FROM NANOBODY® DISCOVERY
AND DEVELOPMENT ALLIANCE"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx